The changing world of drug development

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Cancer drug development faces challenges including high attrition rates and economic pressures.
• Scientific advances in molecular biology (genomics, proteomics, metabolomics) and technology (genome sequencing) are transforming drug discovery.
• The need for rational drug development necessitates integrating diverse stakeholder viewpoints.

Purpose of the Study:

• To illustrate the evolving landscape of cancer drug development.
• To highlight the roles of various stakeholders including patients, researchers, pharmaceutical companies, and regulatory bodies.
• To propose adaptations for facilitating future cancer drug research.

Main Methods:

• Review of current trends and scientific literature in cancer drug development.
• Integration of expert opinions from international stakeholders across the drug development pipeline.
• Analysis of the impact of multi-omics data and technological advancements.

Main Results:

• Cancer drug development is increasingly rational, driven by scientific and technological progress.
• A multi-stakeholder approach is crucial for addressing challenges and improving efficiency.
• The integration of omics data and advanced data handling is key to modern drug discovery.

Conclusions:

• Adapting the drug development process by considering all stakeholder perspectives is essential.
• Future cancer drug research can be facilitated through a more integrated and rational approach.
• Technological advancements and a deeper understanding of molecular biology are reshaping oncology drug development.